ANTHEM BIOSCIENCES LIMITED (ANTHEM): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹958.15 latest close · +24.3% over the last 90 sessions

₹958.15 month-end · +51.0% over 12 months

₹958.15 month-end · +26.2% since Jul '25

52-week range ₹579.15 to ₹989.10 · 1-year volatility 29.2%

Was the rally earned?

+51%share price, 1 yearMultiple-driven

Partly.

Most of the rise came from investors paying a higher multiple (P/E 70.4x to 93.5x); per-share earnings added 16 points.
The share count barely moved.

Net profit growth+17 ptsNet profit rose about 14%, which lifts the price.

P/E change+35 ptsThe P/E rose from 70.4x to 93.5x, which lifts the price.

Share count change-1 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare with other companies

How rough has the ride been?

Maximum drawdown-32.0%recovered 2026-08

1-year volatility29.2%annualised

Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-32.0% (2025-09 peak to 2026-02 low, recovered 2026-08)

-16.4% (2026-09 peak to 2026-10 low, recovered 2026-11)

Most recent volume spikes

2026-09-18: 8.1x the 50-day median, price +0.1% that day

2026-07-22: 12.6x the 50-day median, price -1.6% that day

2026-07-17: 7.2x the 50-day median, price +2.4% that day

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE89thflat vs a year ago
Op. margin98th▲ 3 pts vs a year ago
Revenue growth13th
EPS growth58th
Debt/equity ↓87th▲ 13 pts vs a year ago
Cash cycle ↓60th▲ 28 pts vs a year ago
P/E ↓12th▼ 5 pts vs a year ago
12M momentum77th

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~38%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 122.3x, a holder earning 12%/yr needs earnings to grow about 38.2%/yr for 10 years, then trade at 15x.

Delivered16.4%/yrEPS, last 7 fiscal years · 3-yr avg to 3-yr avg

Gap+21.8 ptsimplied minus delivered

Rank118thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	40.0%	41.3%	42.5%
15x	36.9%	38.2%	39.4%
20x	33.0%	34.2%	35.4%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 38.2%/yr

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹958.15
P/E: 93.5x
ROCE: 30.0%
Market Cap: ₹53963 cr
Revenue (TTM): ₹2002 cr
P/S: 27.0x
P/B: 17.7x
ROE: 19.0%
Operating Margin: 36.0%
Debt / Equity: 0.0x
Promoter Holding: 71.4%
12M Momentum: 51.0%

52-week range

₹579.15₹989.10

92% of the way from its 52-week low to its high

Price risk

1Y volatility

29.2%

Beta vs sector

1-year daily

0.83

Balance sheet & cash

Interest cover

operating profit ÷ interest

100.0x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.89x

Share count, 1Y

unchanged

Are profits backed by cash?

4 of 5checks within range1 near a threshold

Other income reliance17%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 17.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate28%Within range

Median quarterly effective tax rate over about 2.5 years: 28.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.89xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.89x (cash from operations ₹1,255 cr, net profit ₹1,410 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress34% of fixed assetsWithin range

Capital work-in-progress is 34% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Since Sep 2025, DIIs added 6.3 pts; promoters trimmed 3.3 pts; FIIs added 0.9 pts.
The number of shareholders fell from 2.2 lakh to 1.7 lakh (-20%) between Sep 2025 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '25Jun '26Change

Promoters74.7%71.4%-3.3 pts

FIIs1.7%2.6%+0.9 pts

DIIs7.2%13.5%+6.3 pts

Public and others16.4%12.5%-3.9 pts

Number of shareholders

1.7 lakhshareholders-20% since Sep '25

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−17.7%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like ANTHEM BIOSCIENCES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −29% to +6% vs the market, against 0% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −17.6%, 80% range −24.6% to −14.5%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median

−17.7%

All companies' median

−0.1%

Beat the market

32% vs 50%

50 past situations · 50 companies · 27 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
PFIZER Health Technology	Mar 2020	40x	27%	+21%	−12%	−37%
AJANTPHARM Health Technology	May 2020	34x	24%	+46%	0%	−28%
GLAXO Health Technology	May 2024	71x	36%	+101%	0%	+20%
COHANCE Health Technology	Oct 2024	131x	19%	+127%	0%	−44%
BRITANNIA Consumer Non-Durables	Apr 2020	66x	44%	+9%	−6%	−32%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
3MINDIA Producer Manufacturing	Mar 2020	58x	44%	−22%	−25%	−10%
CLEAN Process Industries	May 2025	63x	29%	+19%	−6%	−50%
CRISIL Commercial Services	Oct 2020	43x	42%	+41%	0%	−15%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, size and debt/equity. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ANTHEM BIOSCIENCES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

LINDE INDIALINDEINDIA

Process Industries

67%similar

debt/equitymarket cap

INGERSOLL-RAND (INDIA)INGERRAND

Producer Manufacturing

61%similar

debt/equityrevenue

3M INDIA3MINDIA

Producer Manufacturing

59%similar

debt/equitymarket cap

FINE ORGANIC INDUSTRIESFINEORG

Process Industries

57%similar

debt/equityvolatility

GILLETTE INDIAGILLETTE

Consumer Non-Durables

55%similar

operating marginmarket cap

GLAXOSMITHKLINE PHARMACEUTICALGLAXO

Health Technology

63%similar

market capdebt/equity

CORONA REMEDIESCORONA

Health Technology

55%similar

ROCEP/E

AJANTA PHARMAAJANTPHARM

Health Technology

50%similar

market capROCE

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

8 events since Feb '26

2026
SepPromoterPromoter holding fell 3.2 pts to 71.4%.
AugPriceRegained the 2025-09 peak, 6 months after the low.
JulPriceVolume reached 12.6x its 50-day median on 2026-07-22; price -1.6% that day.
JunInstitutionsFII + DII holding rose 4.0 pts over 2 quarters to 12.8%.
JunDividendStarted paying a dividend (payout 19% of profit).
MayPriceVolume reached 9.7x its 50-day median on 2026-05-29; price +0.4% that day.
MarPriceVolume reached 8.5x its 50-day median on 2026-03-09; price -0.5% that day.
FebPriceFell 32% from the Sep 2025 peak to the Feb 2026 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history17 months · 2025-07 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	93.5x	₹2002 cr	19.0%	30.0%	0.0x
2026-10	80.9x	₹2002 cr	18.9%	30.0%	0.0x
2026-09	83.8x	₹2002 cr	18.9%	30.0%	0.0x
2026-08	84.7x	₹2124 cr	19.5%	30.0%	0.0x
2026-07	76.8x	₹2124 cr	19.5%	30.0%	0.0x
2026-06	73.1x	₹2124 cr	19.5%	30.0%	0.0x
2026-05	88.0x	₹1996 cr	20.1%	28.0%	0.0x
2026-04	88.0x	₹1996 cr	20.1%	28.0%	0.0x
2026-03	76.0x	₹1996 cr	20.1%	28.0%	0.0x
2026-02	76.1x	₹2071 cr	21.4%	28.0%	0.0x
2026-01	65.1x	₹2071 cr	21.4%	28.0%	0.0x
2025-12	70.7x	₹2071 cr	21.4%	28.0%	0.0x
2025-11	70.4x	₹2046 cr	21.0%	28.0%	0.0x
2025-10	78.7x	₹2046 cr	21.0%	28.0%	0.0x
2025-09	84.4x	₹2046 cr	21.0%	28.0%	0.0x
2025-08	101.4x	₹1845 cr	18.7%	28.0%	0.0x
2025-07	94.1x	₹1845 cr	18.7%	28.0%	0.0x

Methodology and data notes